Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
93%
B Cell
49%
Overall Survival
27%
Neoplasm
24%
Non-Hodgkin Lymphoma
23%
Large-Cell Lymphoma
22%
Germinal Center
22%
Follicular Lymphoma
21%
Mantle Cell Lymphoma
21%
Polymerase Chain Reaction
20%
Gene Expression Profiling
20%
B-Cell Lymphoma
20%
Diagnosis
19%
Rituximab
19%
Gene Expression
17%
Biopsy
16%
Disease
15%
Peripheral T-Cell Lymphoma
15%
T Cell
13%
Epstein Barr Virus
13%
Posttransplant Lymphoproliferative Disease
13%
Event Free Survival
12%
Denaturing Gradient Gel Electrophoresis
12%
Hodgkin's Lymphoma
12%
Gene Rearrangement
12%
Specific Tumor
11%
Immunoglobulin Heavy Chain Gene
10%
Formaldehyde
10%
Burkitt's Lymphoma
10%
Immunohistochemistry
9%
Autologous Hematopoietic Stem Cell Transplantation
9%
Prednisone
8%
Cyclophosphamide
8%
Vincristine
8%
Doxorubicin
8%
microRNA
8%
Germinal Center B-Cell Like Diffuse Large B-Cell Lymphoma
8%
International Prognostic Index
8%
T Lymphocyte Receptor
7%
Lymphoproliferative Disease
7%
Anaplastic Large Cell Lymphoma
7%
Molecular Pathology
7%
Pediatrics
7%
MALT Lymphoma
7%
Nodular Lymphocyte Predominant Hodgkin's Lymphoma
7%
Abdominal Aortic Aneurysm
7%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
7%
Lymph Node
6%
Bone Marrow Transplantation
6%
Disease Course
6%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
Gene Expression Profiling
26%
Gene Expression
23%
T Cell
22%
Genetics
16%
Overall Survival
14%
P53
14%
T-Cell Gene Rearrangement
14%
Cytogenetics
13%
Mouse
12%
Cyclin D1
11%
T Cell Receptor
10%
Mdm2
10%
Polymerase Chain Reaction
10%
Gene Mutation
9%
Epstein Barr Virus
8%
Messenger RNA
8%
Microarrays
8%
Gel Electrophoresis
8%
Intravenous Immunoglobulin
7%
DNA Methylation
7%
Immunoglobulin Gene
7%
Survival Prediction
6%
Rituximab
6%
Fluorescence in Situ Hybridization
6%
Clinical Trial
6%
High Risk Population
5%
Clonal Variation
5%
Clonality
5%
Flow Cytometry
5%
Tumor Suppressor Gene
5%
Methylation
5%
Ploidy
5%
Myc
5%
Eicosanoid Receptor
5%
Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
47%
Lymphoma
16%
Mantle Cell Lymphoma
12%
Germinal Center B Cells
11%
Rituximab
11%
Hodgkin Disease
10%
Overall Survival
10%
Follicular Lymphoma
10%
Event-free Survival
10%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
9%
Polymerase Chain Reaction
8%
Molecular Diagnostics
7%
Large B-cell Lymphoma
7%
Immunohistochemistry
7%
Molecular Classification
7%
Tumor
7%
B-cell Lymphoma 2 (Bcl-2)
7%
Genomic Deletion
7%
Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
7%
Lymphomagenesis
7%
Cell of Origin
7%
Clinicopathologic Study
7%
Peripheral T-cell Lymphoma
7%
Murine Double Minute 2 (MDM2)
7%
Nebraska
7%
Primary Mediastinal Large B-cell Lymphoma
7%
Activated B Cells
6%
Cyclin D1 (CCND1)
6%
High-dose Chemotherapy
6%
B Cells
6%
Non-Hodgkin Lymphoma
5%
Denaturing Gradient Gel Electrophoresis
5%
Prognostic Significance
5%
Epstein-Barr Virus
5%
Tissue Microarray
5%
Clonal Relationship
5%
Gene Signature
5%
Anthracyclines
5%